EUCTR2004-000572-14-ES进行中（未招募）1 期
Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capecitabine. - Not applicable
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 162
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •. Histologically or cytologically proven diagnosis of breast adenocarcinoma that is now metastatic (TxNxM1) or locally recurrent and inoperable (T4NxM0).
- •. Patients must have been previously treated with an anthracycline, taxanes (docetaxel and/or paclitaxel), and capecitabine. These treatments may have been given in the adjuvant or metastatic setting, separately or combined.
- •. Patients must not have received more than two previous chemotharapy regimens for metastatic or locally recurrent and inoperable breast cancer.
- •. Evidence of measurable disease as defined by RECIST.
- •. Completion of all prior chemotherapy, immunotherapy (including trastuzumab [Herceptin®]), targeted non-cytotoxic therapy, and radiotherapy more or equal 3 weeks prior to first treatment dose on study. Prior treatment with radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable or non-measurable disease being evaluated for efficacy in this protocol. Patients on stable doses of bisphosphonate therapy for at least 90 days prior to first treatment dose on study may continue such therapy.
- •. ECOG (Eastern Cooperative Oncology Group) performance status of 0,1 or 2.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •. History of any second malignancy with the exception of adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri. Patients with adequately treated contralateral breast cancer which has been disease-free for more than 5 years prior to first treatment dose on study are eligible.
- •. Concurrent treatment with other anti-cancer therapy, including chemotherapy, immunotherapy (including trastuzumab [Herceptin®]), hormonal therapy, radiotherapy, chemoembolization therapy, cryotherapy, targeted therapy, or patients planning to receive these treatments.
- •. Concurrent treatment with potent inhibitors of cytochrome P450 3A4, such as ketoconazole, itraconazole, and clarithromycin, or patients planning to receive these treatments. For patients who were receiving treatment with such agents, a one-week washout period is required before first treatment dose on study.
- •. Prior treatment with epothilones or with non-approved tubulin-interacting agents.
- •. Prior participation in any other trials that involve RPR109881 with a survival endpoint to avoid compromising the results of such trials.
- •. HER2-positive patients who are candidates for Herceptin®.
- •. Known symptomatic brain or leptomeningeal involvement with cancer. Patients with a history of symptomatic brain or leptomeningeal involvement with cancer (i) must have had these lesions previously surgically removed or irradiated; (ii) are not being treated currently with corticosteroids; and (iii) have had documentation that the lesions are stable or improving by CT or MRI scan performed at least 3 months apart. CT or MRI scan of the brain is required only in case of clinical suspicion of central nervous system involvement. Patients with asymptomatic untreated brain lesions are not excluded.
- •. Known human immunodeficiency virus (HIV) infection currently requiring therapy, or acquired immunodeficiency syndrome (AIDS)-related illness.
- •. Patients who are pregnant or breastfeeding.
研究者
相似试验
进行中（未招募）
不适用
Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capecitabine. - Not applicableMetastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine.Classification code 10055113EUCTR2004-000572-14-DKAventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)162
进行中（未招募）
不适用
Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capecitabine. - Not applicableEUCTR2004-000572-14-BEAventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)162
进行中（未招募）
1 期
Proof-of-concept study for BIVV020 in chronic inflammatory demyelinating polyneuropathy (CIDP)Chronic inflammatory demyelinatingpolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10077384Term: Chronic inflammatory demyelinating polyneuropathySystem Organ Class: 100000004852EUCTR2020-004006-54-FRSanofi-Aventis Recherche & Développement90
进行中（未招募）
不适用
A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unresectable squamous cell carcinomaPatient with locally advanced non-resectable squamous cell carcinoma of the head and neck stage III or IV, oral, oropharyngeal, laryngeal or hypopharyngeal cancer, non-resectable.EUCTR2006-002187-25-SERadiumhemmet, Karolinska University Hospital90
进行中（未招募）
1 期
Treatment with IPH5201 and durvalumab in patients with Non-Small Cell Lung CancerEUCTR2022-001903-42-GRInnate Pharma SA70